ID
42476
Descrizione
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).
collegamento
Keywords
versioni (3)
- 02/07/21 02/07/21 - Sarah Riepenhausen
- 15/07/21 15/07/21 - Sarah Riepenhausen
- 16/07/21 16/07/21 - Sarah Riepenhausen
Titolare del copyright
LEOSS
Caricato su
16 luglio 2021
DOI
10.21961/mdm:42476
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
Descrizione
Antibodies: CD-22
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0054947
Descrizione
Antibodies: CD-38
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0075742
Descrizione
Antibodies: CD-52
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1610534
Descrizione
Antibodies: Anti-CD79b
Alias
- UMLS CUI-1
- C0104979
- UMLS CUI-2
- C0003241
Descrizione
Antibodies: B Lymphocyte stimulator-specific inhibitor (BLyS)
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C3160093
Descrizione
Antibodies: CD19-BiTE
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C4727095
Descrizione
Antibodies: Complement inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1564892
Descrizione
Crovalimab
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C1564892
- UMLS CUI [1,2]
- C3846158
Descrizione
Eculizumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C1541483
Descrizione
Pegcetacoplan (APL-2)
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C4053680
Descrizione
Ravulizumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C4550350
Descrizione
Antibodies: Integrin antagonists
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C2917367
Descrizione
Antibodies: Interleukin inhibitors
Alias
- UMLS CUI-1
- C3653320
- UMLS CUI-2
- C0003241
Descrizione
Basiliximab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0676831
Descrizione
Canakinumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C2718773
Descrizione
Ixekizumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C3489764
Descrizione
Sarilumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C3885145
Descrizione
Secukinumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C3179547
Descrizione
Tocilizumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C1609165
Descrizione
Ustekinumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C1608841
Descrizione
Antibodies: TNF-alpha inhibitors
Alias
- UMLS CUI-1
- C3653350
- UMLS CUI-2
- C0003241
Descrizione
Adalimumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C1122087
Descrizione
Certolizumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C1872109
Descrizione
Etanercept
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0717758
Descrizione
Golimumab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C2353893
Descrizione
Infliximab
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0666743
Descrizione
Other Antibodies
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0205394
Descrizione
Inhibitors: Co-stimulation inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1622572
- UMLS CUI-3
- C1999216
Descrizione
Inhibitors: Calcineurin inhibitors
Alias
- UMLS CUI-1
- C1562036
Descrizione
Inhibitors: Interleukin inhibitor
Alias
- UMLS CUI-1
- C3653320
Descrizione
Inhibitors: JAK inhibitors
Alias
- UMLS CUI-1
- C3854325
Descrizione
Baricitinib
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C4044947
Descrizione
Fedratinib
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C3886623
Descrizione
Ruxolitinib
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C2931926
Descrizione
Tofacitinib
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C2930696
Descrizione
Upadacitinib
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C4726929
Descrizione
Inhibitors: mTOR inhibitors
Alias
- UMLS CUI-1
- C2746052
Descrizione
Inhibitor: PDE-4-inhibitor
Alias
- UMLS CUI-1
- C2936609
Descrizione
Other Inhibitors
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0243077
Descrizione
Checkpoint inhibitors: last 3 months
Alias
- UMLS CUI-1
- C0332185
- UMLS CUI-2
- C4733472
Descrizione
In case of combination therapy please indicate all of the respective drugs.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3657270
Descrizione
In case of combination therapy please indicate all of the respective drugs.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3658706
Descrizione
In case of combination therapy please indicate all of the respective drugs.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C1367202
Descrizione
In case of combination therapy please indicate all of the respective drugs.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
Descrizione
Indicate recent other checkpoint inhibitor
Tipo di dati
text
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
- UMLS CUI [1,4]
- C1521902
Descrizione
No recent checkpoint inhibitor therapy
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C1298908
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Descrizione
Unknown Checkpoint inhibitor therapy
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0439673
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Descrizione
Chemotherapeutics: Antimetabolites
Alias
- UMLS CUI-1
- C0003376
- UMLS CUI-2
- C0729502
Descrizione
6-Mercaptopurine
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0000618
Descrizione
Azathioprine
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0004482
Descrizione
Leflunomide
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0063041
Descrizione
Methotrexate
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0025677
Descrizione
Mycophenolate mofetil / Mycophenolic acid
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0209368
- UMLS CUI [2]
- C0026933
Descrizione
Sulfasalazine
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0036078
Descrizione
Teriflunomide
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C1718383
Descrizione
Chemotherapeutics: Cytostatics
Alias
- UMLS CUI-1
- C0010858
- UMLS CUI-2
- C0729502
Descrizione
Recent: Cladribine (2-CDA) i.v./s.c.
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
- UMLS CUI [2,1]
- C0092801
- UMLS CUI [2,2]
- C0021499
- UMLS CUI [2,3]
- C0332185
Descrizione
Recent: Cladribine (2-CDA) p.o.
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Descrizione
Recent: Cyclophosphamide i.v.
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
Descrizione
Recent: Cyclophosphamide p.o.
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Descrizione
Recent: Mitoxantrone
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0026259
- UMLS CUI [1,2]
- C0332185
Descrizione
Other Chemotherapeutics
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0729502
Descrizione
Other Chemotherapeutics
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0729502
Descrizione
Indicate other Chemotherapeutics
Tipo di dati
text
Alias
- UMLS CUI [1,1]
- C0729502
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Descrizione
Other immunosuppressive regimens: Corticosteroids
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0001617
Descrizione
low dose prednisolone equivalent
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0445550
- UMLS CUI [1,2]
- C0038317
Descrizione
medium dose prednisolone equivalent
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0439536
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0038317
Descrizione
high dose prednisolone equivalent
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0038317
- UMLS CUI [1,2]
- C0444956
Descrizione
Other immunosuppressive regimens: Fumarate
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0220833
Descrizione
Dimethyl fumarate
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0058218
Descrizione
Dimethyl fumarate/ethyl hydrogen fumarate (Fumaderm)
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0058218
- UMLS CUI [1,2]
- C0059764
- UMLS CUI [2]
- C0633802
Descrizione
Other immunosuppressive regimens: Immunoglobulines
Alias
- UMLS CUI-1
- C1963758
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0021081
Descrizione
Other immunosuppressive regimens: Interferon
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C3652465
Descrizione
Other immunosuppressive regimens: Other Multiple Sclerosis drugs
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0013227
- UMLS CUI-4
- C0026769
Descrizione
Other immunosuppressive regimens
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0021081
Descrizione
Other immunosuppressive drugs
Tipo di dati
integer
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
Descrizione
Indicate other immunosuppressive drugs
Tipo di dati
text
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Descrizione
Immunosuppressive drugs: Underlying disease
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C3146298
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0026769
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205494
- UMLS CUI [1,4]
- C0004364
- UMLS CUI [1,5]
- C0205394
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205478
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0029216
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C3495832
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
Descrizione
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
- UMLS CUI [1,5]
- C1521902
Descrizione
Indication for immunosuppressive drugs: Unknown underlying disease
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0277554
Descrizione
Is data entry for this section finished?
Alias
- UMLS CUI-1
- C4684556
- UMLS CUI-2
- C1828479
- UMLS CUI-3
- C0205197
Similar models
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0003241 (UMLS CUI-2)
C3160093 (UMLS CUI-2)
C0332185 (UMLS CUI [1,2])
C1564892 (UMLS CUI-2)
C2917367 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C1521902 (UMLS CUI [1,2])
C0003241 (UMLS CUI [1,3])
C1622572 (UMLS CUI-2)
C1999216 (UMLS CUI-3)
C1521902 (UMLS CUI [1,2])
C0243077 (UMLS CUI [1,3])
C4733472 (UMLS CUI-2)
C3657270 (UMLS CUI [1,2])
C3658706 (UMLS CUI [1,2])
C1367202 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0729502 (UMLS CUI-2)
C0026933 (UMLS CUI [2])
C0729502 (UMLS CUI-2)
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0092801 (UMLS CUI [2,1])
C0021499 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C0729502 (UMLS CUI-2)
C0729502 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0205394 (UMLS CUI-2)
C0001617 (UMLS CUI-3)
C0038317 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
C0444956 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C0220833 (UMLS CUI-3)
C0059764 (UMLS CUI [1,2])
C0633802 (UMLS CUI [2])
C0205394 (UMLS CUI-2)
C0021081 (UMLS CUI-3)
C0348016 (UMLS CUI [1,2])
C0021499 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C3652465 (UMLS CUI-3)
C0205394 (UMLS CUI-2)
C0013227 (UMLS CUI-3)
C0026769 (UMLS CUI-4)
C0021081 (UMLS CUI-2)
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C3146298 (UMLS CUI-2)
C3146298 (UMLS CUI [1,2])
C0026769 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,3])
C0004364 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0205478 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0029216 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C3495832 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0277554 (UMLS CUI [1,4])
C1828479 (UMLS CUI-2)
C0205197 (UMLS CUI-3)
C1828479 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])